Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR-MD-02 for NASH Cirrhosis and Portal Hypertension (NASH-CX)
NCT02462967Phase 2Completed
- Sponsor
- Galectin Therapeutics
- Start
- Jun 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belapectin in Nonalcoholic steatohepatitis (NASH), Liver cirrhosis (LC) and Portal Hypertension (PH) (3 arms), sponsored by Galectin Therapeutics. Primary endpoint: Hepatic Venous Pressure Gradient at 1 year. Started Jun 2015; status: completed.
02
Drugs
belapectin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT02462967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462967.